News roundup Friday, January 24

The latest from BioStock

» Neko Health raises $260 million
» Flerie is gearing up for 2025
» China shows its leadership in drug development
» Xintela aims for new milestones in 2025
» Recruitment halfway through – Lipidor expects results in April

Read the newsletter for v.3 here.

The latest news

is investing 820 million Canadian dollars in Canada to create more than 700 high-skilled jobs across all areas of the business. Read more.

The contract negotiations between Q-linea, Inc. and a large American reference laboratory are continuing and an agreement is expected in February 2025. Read more.

BioPorto publishes reference ranges using their NGAL immunoassay in healthy adults and children. Read more.

Nanexa carries out a directed issue of units of SEK 35 million and raises a loan of SEK 20 million. Read more.

Camurus issues reverse profit warning for Q4 and full year 2024. Read more.

Carbiotix is carrying out a directed issue of shares of a maximum of approximately SEK 3,92 million. Read more.

Monivent confirms that the communicated rights issue is 100 percent secured. Read more.

Toleranzia provides an update on the clinical trial application. Read more.

SciBase announces that Nevisense (EIS) is included in updated German guidelines for image analysis. Read more.

Newbury Pharmaceuticals secures generic approval for pomalidomide capsules. Read more.

NanoEcho increases the degree of collateralization in the rights issue and publishes a memorandum. Read more.

Today is the end of the subscription period in Thor Medicals subsequent offer. Read more.

Inify Laboratories announces the final result of the subsequent Offering. Read more.

Genmab provides information about share rights and warrants to employees. Read more.

ChemoTech has updated its website for a more detailed explanation of its TSE technology. Read more.

Invitation

Arjo  CellaVision

Calling

Nanexa

Report

Newbury Pharmaceuticals

This morning's price development